Table 12:
Expression of Broad-Spectrum Epithelial Markers, p63/p40/TTF-1, and SMA/Desmin in Sarcomatoid Carcinoma
| Marker | All Sites(541, 542) | Bladder(444, 543–551) | Breast(552–558) | Head and Neck(543, 549, 559–565) | Lung*(543, 566–570) | Skin(571–573) |
|---|---|---|---|---|---|---|
| p63 | 65% (212/325) | 53% (26/49) | 78% (83/106) | 64% (41/64) | 50% (10/20) | 73% (32/44) |
| AE1/AE3 | 64%** (305/477) | 87% (55/63) | 71% (76/107) | 55% (58/105) | 97% (57/59) | 67% (8/12) |
| CAM5.2 | 64% (229/358) | 77% (46/60) | 26% (15/58) | 31% (18/58) | 93% (137/148) | 58% (7/12) |
| 34βE12 | 53% (62/116) | 39% (14/36) | ND | 58% (15/26) | ND | 100% (12/12) |
| EMA | 47% (130/278) | 64% (35/55) | 31% (29/93) | 23% (12/53) | 76% (42/55) | ND |
| p40 | 30% (48/159) | ND | 58% (21/36) | 54% (20/37) | 8% (7/86) | ND |
| CK5/6 | 17% (31/179) | 27% (6/22) | ND | 25% (2/8) | 14% (17/122) | ND |
| MOC-31 | 16% (11/68) | 0% (0/11) | ND | 4% (3/19) | 12% (8/38) | ND |
| SMA | 32% (57/181) | 23% (12/52) | 71% (15/21) | 46% (6/13) | 28% (16/57) | 8% (1/12) |
| Desmin | 8% (17/222) | 8% (6/74) | 0% (0/15) | 15% (2/13) | 11% (9/82) | 0% (0/12) |